Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
Study is designed to assess the efficacy and safety of memantine XR and pregabalin in
 reducing neuropathic pain in patients with chemotherapy-induced peripheral neuropathy (CIPN)
 caused by prior treatment with any chemotherapy as measured by the Brief Pain Inventory-
 Short Form (BPI-SF). It will also determine the influence of these drugs on peripheral
 neuropathy-related functional status and quality of life (QOL) as measured by the EORTC
 QLQ-C30.
Using an observational, case-only, prospective design, potential subjects will be identified
 from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be
 treated with memantine XR-pregabalin combination therapy. The primary objective is to assess
 the efficacy of memantine XR and pregabalin in reducing neuropathic pain as measured by the
 Brief Pain Inventory- Short Form (BPI-SF). Patients who agree to participate will be asked to
 complete study questionnaires prior to the start of their CIPN treatment and once per week
 for six weeks during their treatment. After this period, patients will be contacted once per
 month for three months to assess interval medical history, concomitant medications, and
 adverse events.
Inclusion Criteria:

 Ability to understand and the willingness to sign a written informed consent. History of
 any type of cancer treated with chemotherapy.

 Chemotherapy induced peripheral neuropathy (CIPN) due to:

 -  Cisplatin, carboplatin, and oxaliplatin

 -  Taxanes- paclitaxel, docetaxel, and cabazitaxel

 -  Thalidomide, lenalidomide, and pomalidomide

 -  Plant alkaloids, such as vinblastine, vincristine, vinorelbine, and etoposide

 -  Epothilones, such as ixabepilone

 -  Bortezomib, carfilzomib

 -  Eribulin Planning to receive treatment for CIPN with memantine XR and pregabalin.
 Average daily neuropathic pain intensity > 4 measured by item #5 of BPI-SF (Average
 daily pain at baseline is the average of pain scores over the last 7 days before
 enrolling patients in to the study).

 CIPN > grade 1 as measured by NCI-CTCAE v 4.0. Must be ≥ 3 months beyond completion of
 chemotherapy. Not planning to receive concurrent chemotherapeutic agents during the study
 period.

 Patients with diabetes mellitus, peripheral vascular disease, HIV infection, or a
 significant degenerative or familial neurologic can be included in the study provided they
 don't have peripheral neuropathy secondary to above mentioned diseases.

 Allowable types and amount of prior therapy for neuropathy:

 -  Patients receiving analgesics for pain associated with CIPN are eligible provided they
 have taken the same dosage and same medication for at least 2 weeks prior to the study
 initiation.

 -  Patients on antidepressants regimens of Selective Serotonin Reuptake Inhibitors (SSRI)
 or Selective serotonin norepinephrine reuptake inhibitors (SSNRI) for treatment of
 anxiety or depression, anticonvulsants or mexiletine for the treatment of pain are
 eligible provided they are on stable dose for 30 days.

 Age ≥ 18 years. Both men and women of all races and ethnic groups are eligible for this
 trial.

 Exclusion Criteria:

 Any pain other than neuropathic pain of equal or greater severity. Patients with sensory
 polyneuropathy due to AIDS/HIV, complex regional pain syndrome, and Trigeminal neuralgia.

 History of suicidal ideation. Patients with a history of non-compliance. Patients who are
 judged by the investigator to be unable or unlikely to understand the nature, scope, and
 possible consequences of the study.